Parkwood LLC cut its position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 24.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 323,000 shares of the company's stock after selling 103,620 shares during the period. Parkwood LLC owned about 0.53% of Monte Rosa Therapeutics worth $2,242,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its stake in Monte Rosa Therapeutics by 192.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,443 shares of the company's stock valued at $38,000 after acquiring an additional 3,584 shares during the period. GAMMA Investing LLC grew its position in shares of Monte Rosa Therapeutics by 10,665.5% in the 4th quarter. GAMMA Investing LLC now owns 5,921 shares of the company's stock valued at $41,000 after purchasing an additional 5,866 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Monte Rosa Therapeutics in the fourth quarter valued at approximately $43,000. Virtus ETF Advisers LLC acquired a new position in Monte Rosa Therapeutics in the 4th quarter worth $63,000. Finally, Focus Partners Wealth bought a new position in shares of Monte Rosa Therapeutics in the fourth quarter valued at about $77,000. Institutional investors and hedge funds own 79.96% of the company's stock.
Insider Buying and Selling
In other Monte Rosa Therapeutics news, Director Chandra P. Leo acquired 10,000 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Monday, March 24th. The stock was acquired at an average cost of $5.84 per share, for a total transaction of $58,400.00. Following the purchase, the director now owns 10,000 shares of the company's stock, valued at approximately $58,400. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 6.90% of the stock is owned by corporate insiders.
Monte Rosa Therapeutics Price Performance
Shares of NASDAQ:GLUE opened at $4.04 on Wednesday. Monte Rosa Therapeutics, Inc. has a one year low of $3.21 and a one year high of $12.40. The company has a market cap of $248.50 million, a price-to-earnings ratio of -2.21 and a beta of 1.52. The firm has a 50 day simple moving average of $4.97 and a 200 day simple moving average of $6.52.
Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.57 EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.81. The firm had revenue of $84.93 million during the quarter, compared to the consensus estimate of $13.57 million. As a group, analysts expect that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on the stock. Wedbush reiterated an "outperform" rating and issued a $17.00 price target (up previously from $15.00) on shares of Monte Rosa Therapeutics in a research note on Thursday, March 20th. Lifesci Capital initiated coverage on Monte Rosa Therapeutics in a report on Wednesday, March 12th. They issued an "outperform" rating and a $19.00 target price on the stock. Finally, Wells Fargo & Company lowered their price target on Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating for the company in a report on Friday, March 21st.
Check Out Our Latest Report on Monte Rosa Therapeutics
Monte Rosa Therapeutics Company Profile
(
Free Report)
Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Monte Rosa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.
While Monte Rosa Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
